Wisconsin device-maker Neuwave Medical just raised a $25 million equity round from 38 investors, according to a regulatory filing.
The company has a whole suite of cancer ablation tools, and many of which have received FDA approval. They use microwaves to kill tumor cells – a useful alternative to surgery for some patients, particularly those too ill to undergo the knife.
Its lead product, the Certus 140 Microwave Ablation System, allows microwaves to be administered to a tumor site with a super-thin flexible probe – allowing higher levels of energy to be administered with high site specificity. Here’s how it works:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
[youtube http://www.youtube.com/watch?v=B_BQMGnb7rg]
Since Neuwave’s 2004 launch, it has now raised about $100 million in venture funding. The company has yet to call back to discuss what it’ll do with this latest funding round.
Previous investors have included Venture Investors, HIG BioVentures, the Wisconsin Alumni Research Foundation and the State of Wisconsin Investment Board.
